众所周知,慢性髓性白血病(CML)在髓性增生性系统疾病中具有重要位置。这一方面是由于其好发率,其相对值约占髓性增生疾病的60％,在世界范围内成年人绝对发病数则为0.3×10~5～1.5×10~5人,相当于淋巴性恶性肿瘤(如慢性淋巴性白血病)的发病数;另一方面显示CML不仅通过多潜能干细胞的克隆性转化,而且还有一种特异遗传标志的出现(phi-染色体,bcr-abl易位),首先酪氨酸激酶活性调节发生改变, It is well-known that chronic myelogenous leukemia (CML) has an important place in myeloproliferative disorders. This is because of its high incidence rate, its relative value accounts for about 60% of myeloproliferative diseases in the world, the absolute incidence of adults was 0.3 × 10 ~ 5 ~ 1.5 × 10 ~ 5, the equivalent of lymph Malignant tumors such as chronic lymphocytic leukemia; on the other hand, CML is not only clonally transformed by pluripotent stem cells, but also has the appearance of a specific genetic marker (phi-chromosome, bcr-abl translocation) First tyrosine kinase activity regulation changes,